Dan Vogl, MD
Enriched profileAssociate Professor of Medicine (Hematology-Oncology), Hospital of the University of Pennsylvania; Medical Director, Abramson Cancer Center Clinical Research Unit · University of Pennsylvania
Dan Vogl is Associate Professor of Medicine (Hematology-Oncology), Hospital of the University of Pennsylvania; Medical Director, Abramson Cancer Center Clinical Research Unit at University of Pennsylvania. OpenAlex indexes 365 publications with 18,237 citations (h-index 50); ClinicalTrials.gov lists 7 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Dan Toby Vogl, MD, is Associate Professor of Medicine (Hematology-Oncology), Hospital of the University of Pennsylvania. The public record shows 365 publications with 18,237 citations (h-index 50), centered on Multiple Myeloma Research and Treatments, CAR-T cell therapy research, Protein Degradation and Inhibitors. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 13 companies, 4 NIH-funded awards (2009–2026).
- Most recent indexed publication: 2026 · Blood cancer journal
- Top research focus: Multiple Myeloma Research and Treatments
- 7 registered trials on ClinicalTrials.gov
- Open Payments reporting from 13 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 30 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 124.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:
- Tasquinimod for the Treatment of Relapsed or Refractory Myeloma
Sponsor: University of Pennsylvania
- Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Sponsor: CellCentric Ltd.
- Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
Sponsor: Abramson Cancer Center at Penn Medicine
Industry payments
Updated 27 Aug 2026
13 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Teva Pharmaceuticals USA, Inc.Program year20252 payments
- GENZYME CORPORATIONProgram year20252 payments
- Janssen Scientific Affairs, LLCProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
50.5%Thalidomide Analog40.5%Lenalidomide59%Pomalyst23%Revlimid18%Part D<11 patientsProteasome Inhibitor5.4%Ninlaro100%Part D<11 patientsDermatology
22.2%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor22.2%Acyclovir100%Part D≥26 patientsAnti-infectives
11.1%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor7.7%Valacyclovir100%Part D≥11 patientsShort-acting sulfonamides3.4%Sulfamethoxazole-Trimethoprim100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
4 NIH research awards on record, funded 2009–2026 per NIH RePORTER. The latest:
Congress activity
Updated 27 Aug 2026
63 congress contributions (2006–2025) across AACR, ASCO, ASH per OpenAlex. The most recent:
- Clinical activity of novel targeting of S100A9 with tasquinimod for relapsed and refractory multiple myeloma (RRMM).
ASCO Annual Meeting
ASCO2025Presenting author - Disease response at apheresis and association with long-term outcomes following CAR-T cells for relapsed/refractory multiple myeloma (RRMM).
ASCO Annual Meeting
ASCO2025Co-author - CCR5 blockade: A therapeutic approach to uncouple CART-BCMA expansion from CART-mediated immune toxicities.
ASH Annual Meeting
ASH2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
Most-cited works
by citation count (OpenAlex)Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/dan-vogl-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/profile/Dan-Vogl
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - X / Twitter
x.com/danvogl
Mentions by others
where others cite or feature them- Other
lls.org/award-recipient/dan-vogl
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lls.org ↗ - Other
onclive.com/authors/dan-vogl-md-msce
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - Other
vjhemonc.com/speaker/dan-vogl
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjhemonc.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗
- Board certified in Internal Medicine
Medical Oncology, and Hematology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pennmedicine.org ↗ - Internal medicine residency
Columbia-Presbyterian Medical Center, New York
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pennmedicine.org ↗ - Hematology-Oncology fellowship
Hospital of the University of Pennsylvania, Philadelphia
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pennmedicine.org ↗
Editorial & leadership roles
journal and society appointments- Medical Director
Abramson Cancer Center Clinical Research Unit (oversees 140+ research nurses, coordinators, and biospecimen staff managing 300+ active cancer clinical trials)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗ - Senior Scholar
Center for Clinical Epidemiology and Biostatistics (CCEB), University of Pennsylvania
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cceb.med.upenn.edu ↗ - Member
Penn Myeloma Program, Amyloidosis Program, and Cellular Therapy and Transplant Program
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthtree.org ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lls.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
- Video interview speaker profile
VJHemOnc (hematology/oncology video journal)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjhemonc.com ↗ - Podcast guest
HealthTree/Myeloma Crowd Radio - "Tasquinimod As a New Myeloma Therapy with Dan Vogl" (with Yulia Nefedova, Wistar Institute)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthtree.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Carl June, MD
University of Pennsylvania
Harold Feldman, MD
University of Pennsylvania
Howard Herrmann, MD
University of Pennsylvania
Robert Vonderheide, MD
University of Pennsylvania